Teladoc faces activist shareholder challenge, demanding $200M stock buyback, business spinoffs, cost cuts

April 3, 2026 | by | 2 Comments

Languishing Teladoc faces activist shareholder as Q1 reporting nears. Pineal Capital Management, a Dublin, Ireland-based investment firm, issued on Tuesday an open letter to Teladoc’s board, management, and fellow shareholders. The letter publicly revealed their differences with management on the disconnect between the present low value of the stock (TDOC is trading in the $5 range), advocating unlocking what they term ‘the true embedded value of the business and significantly misprices its positive, longer-term prospects.”

While Pineal positioned Teladoc’s current situation as the global leader in virtual healthcare with a 100 million member base, it blamed the company’s “distressed-level valuation” — trading at 4.18 times enterprise value to EBITDA — on multiple management mistakes. These began with the 2020 acquisition of Livongo (a near-fatal self-inflicted error) and now extend to capital spent on bolt-on acquisitions proven to be not accretive to revenue at present, no presentation to shareholders of a multi-year business plan by management to increase share price (down 90% from pre-COVID highs), and share dilution through too many shares outstanding–177 million at present from 90 million in 2020. 

Pineal’s remedy list is not unexpected and cuts straight to the chase:

  • Increasing cost efficiencies, primarily additional cost cutting. 
  • A share buyback up to $200 million to reduce dilution. 
  • Exploring a break-up of the two core businesses – Integrated Care and BetterHelp – into separate entities, via a sale or spin-off transaction.

It believes that Teladoc has plenty of upside due to expanding reimbursement for virtual healthcare, lower out of pocket costs (including permanent first-dollar coverage in high-deductible health care plans and two rural health support programs), their launch of their new 24/7 Virtual Care Platform, a shift for BetterHelp’s behavioral telehealth to an insurance-based payer model boosting conversion and lifetime value–expected to grow to a $100 million run rate in 2026, and international expansion, the real boost for BetterHelp. (This Editor notes that the ‘bolt-on’ acquisition of UpLift was a part of BetterHelp’s conversion to a payer model–see below.)

BetterHelp is Pineal’s primary focus in the letter as the ‘crown jewel’ versus the older Integrated Care platform. Pineal notes the recent $835 million acquisition by UHS of Talkspace, another telementalhealth provider with a checkered track record, as an argument for a BetterHelp  spinoff or sale. 

The ‘or else’, always a part of these activist challenges, is concern “that continued inaction risks a private-market bid at a level well below true intrinsic value”, poison to major shareholders.

Pineal owns TDOC shares through its Pineal Capital Fund 1. The number of shares was not disclosed nor is known through filings in Ireland or the open letter.

What this all means. Or could mean.

Teladoc’s 2025 was flat versus the prior year–retrospectively an improvement versus the bloodlettings of prior years. But their 2026 projection was also flat. In 2025, BetterHelp, their behavioral telehealth unit, fell 9% year over year to $950.4 million in revenue. In reporting 2025 results, Teladoc announced that the Integrated Care business would move from subscription models to visit-based revenue to compensate for enrollment reductions at some client health plans in government programs and reductions in ACA subsidies.

It’s a mystery why Pineal sees BetterHelp as a ‘crown jewel’ when for 2026, Teladoc is projecting a 7% revenue reduction. This Editor has not forgotten that BetterHelp was also seen by former CEO Jason Gorevic (exited 2024) as the future of the company. In May 2025, Teladoc added insurance coverage to primarily DTC BetterHelp by acquiring UpLift for $30 million.

There have been some gains in the share price (about 6%) but it closed today slightly down at $5.28. Stock analyst Zachs isn’t exactly bullish on Q1 results to be reported on 29 April. Revenue projections are down 2.71% to $612.3 million versus Q1 2025, with EPS down $0.3, a 58% drop versus Q1 2025. The year looks equally down with revenue of $2.51 billion, essentially flat to down -0.81%. Yahoo Finance

But…there’s more, just like the direct response commercials.

A further analysis in Bitget shows that total institutional holdings in Teladoc declined by 29.4%. CEO Chuck Divita sold 27,731 shares on 11 March, reducing his direct stake by 7% to roughly $2 million. Yet for some reason, investor Ray Dalio through his firm Bridgewater Associates has been buying on dips, notably increasing its Teladoc stake by 151,000 shares or 31.2% in Q4 2025. However, this can be attributed to speculation to salvage a small (.01%) but underwater position. 

It is clear that Pineal is pushing for a greater valuation of Teladoc shares, as well as a buyback that would bolster their fund’s cash position. It’s an educated guess, but they are not going to be alone among the battered shareholders, either. Watch for another shoe drop around the Q1 earnings report on 29 April.

Coverage from Reuters, Investing.com, 

Some more Ladders, tall and short: telepsych Grow Therapy’s $150M Series D, UnityAI’s $8.5M Series A; Health Recovery Solutions buys Rimidi

March 5, 2026 | by

Standalone telementalhealth continues to be generously funded. Grow Therapy’s $150 million Series D brings their total funding to $328 million and their valuation to $3 billion. Their combination of in-person and telehealth visits with clinicians and psychiatrists is targeted to health plans, employers, and health systems. In-network plans include Humana, Cigna, UnitedHealthcare and Aetna. The fresh funding will be for expansion to the employer benefits market, within health systems for integration with primary care, and additional advanced AI tools. Grow claims that in 2025, they facilitated seven million visits, for a total since inception of 10 million therapy and medication management appointments. The round was led by TCV and Growth Equity at Goldman Sachs Alternatives, which had previously led Grow Therapy’s Series B and C respectively. Participating were new investors BCI and Menlo Ventures plus existing investors Sequoia Capital, SignalFire, and Transformation Capital. Grow joins well-funded competition Spring Health, with a valuation of $3.3 billion and Headway, with a $2.3 billion valuation.​ Blog/Release, Mobihealthnews, MedCity News, Reuters

UnityAI passes the Series A bar with $8.5 million. The round was led by Third Prime, with participation from Nashville Capital Network, Whistler Capital Partners, Max Ventures, Company Ventures, and other existing investors for a total funding of $15 million. Nashville-based UnityAI is a startup developing agentic AI to assist healthcare staff in scheduling for outpatient and specialty care practices. The agents assist with scheduling and rescheduling, confirmations, follow-ups, and referrals. It also integrates staffing operations – capacity optimization, shift management, PTO, and coverage–with the agents into what they call a “single continuously operating system”. The new funding will support continued efforts to scale go-to-market execution and extend its AI-powered operational capabilities. UnityAI integrates with major EHRs and is currently operating 300,000 patient interactions per month across hundreds of sites of care. UnityAI release, Mobihealthnews

And in local (to this Editor) news, Health Recovery Solutions buys Rimidi. Not the Italian Adriatic resort, Rimidi is an Atlanta-based software and services provider for chronic disease management and remote patient monitoring for diabetes and cardiometabolic conditions. Physician founded, it targeted to health systems, physician practices, value-based care organizations, and community health centers such as FQHCs and RHCs. No acquisition cost nor staff transition were disclosed. Dr. Lucienne Ide, MD, PhD Rimidi’s CEO and founder, joins HRS as chief medical officer.

Health Recovery Solutions (HRS) provides remote patient monitoring (RPM), chronic care management (CCM), and longitudinal virtual care. Headquartered in Hoboken, NJ across the Hudson from NYC, its last raise was $70 million in Series C funding back in 2021 via Edison Partners and LLR Partners. Several online sources report a revenue run rate between $23 and $50 million. Rimidi was relatively small, with its last funding in 2023 for $5 million, totaling $12.9 million from investors such as Eli Lilly and Village Capital. Notably, it was woman-led. The acquisition is expected to strengthen HRS’ EHR integrations and in managing diabetes and metabolic diseases within HRS’ PatientFirst Pathways care model. Release

Now a virtual therapist

May 23, 2013 | by

“Ellie” the Virtual Analyst has it right down to the  ‘uh-huhs’  in responding to her patients, but she really excels at taking the measure of body language. According to the NPR interview with University of Southern California’s (USC) Institute for Creative Technologies’ lead developers, psychologist Albert “Skip” Rizzo and computer scientist Louis-Philippe Morency, “Ellie tracks and analyzes around 60 different features — various body and facial movements, and different aspects of the voice. The theory of all this is that a detailed analysis of those movements and vocal features can give us new insights into people who are struggling with emotional issues. The body, face and voice express things that words sometimes obscure.” Movement is tracked by Microsoft Kinect, voice by a microphone. This is the flip side of their original telementalhealth research from last year with simulations of virtual patients for training psychiatric residents [TTA 14 Aug] and PTSD assessment [TTA 28 Oct 11]. Like both of these, this was originally commissioned by the US Department of Defense for PTSD diagnosis, so Ellie provides a report at the end of each session. Your Editor also thinks there’s commercialization potential in the growing category of ‘couch apps’. [TTA 11 May] If Your Shrink Is A Bot, How Do You Respond?

HealthSpot, Netsmart ally for telemedicine kiosks

May 7, 2013 | by

HealthSpot, which debuted its staffed telemedicine/telehealth Stations at CES 2013 (and this Editor previewed at CES New York in November), is partnering with behavioral health EHR/practice/clinical case management software provider Netsmart to add that capability to its kiosk consults. Announced at ATA yesterday, the MedCityNews article is sketchy on exactly how this will be integrated–will it be an option or will select kiosks be dedicated to behavioral health only–but this is likely a first for telementalhealth (another term in our lexicon!) Kiosk placements can be especially useful in rural areas which have a paucity of mental health/psychiatric providers (see TTA on Forefront TeleCare’s ATA announcement). It also follows this year’s ATA theme of telemedicine to more effectively serve rural US areas. HealthSpot also announced a pilot with Nationwide Children’s Hospital in its hometown of Columbus, Ohio; their CEO claims it has orders for 150 units in hand for its now three health system partners. Surprisingly, as of April they are already at Series C funding with a $10.4 million financing (of a $20 million offering) from giant Cardinal Health and other private investors.